PROK PROKIDNEY CORP

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025

WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX.

The titles for the accepted abstracts are provided below and accessible online at:

Late-Breaking Poster Presentation

Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)

Session Title: Late-Breaking Science Posters [LB-PO]

Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST

Poster Board #: TH-PO1203

Other Poster Presentation

Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel

Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600]

Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST

Poster Board #: TH-PO0575

Following the event, a copy of the poster presentations will be available on the Company’s website at:

Additional information on ASN Kidney Week 2025 can be accessed online at:

About ProKidney Corp.

ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit .

ProKidney Contact

Ethan Holdaway

Media Contact

Audra Friis 

Investor Relations Contact

Daniel Ferry



EN
20/10/2025

Underlying

PROKPROKIDNEY CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROKIDNEY CORP

 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Announces Two Abstracts Selected for Presentation at the Ame...

ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025 WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX. The tit...

12h / 47m 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Participate in Two Upcoming Conferences: the Citi Biophar...

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference WINSTON-SALEM, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the following two upcoming healthcare conferences in September: Citi Biopharma Back to School Conference (Boston)Date:Wednesday, September ...

August 27, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Reports Second Quarter 2025 Financial Results and Provides R...

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates FDA confirmed at a July 2025 Type B meeting and in the subsequent meeting minutes that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with type 2 diabetes and advanced CKD; FDA also confirmed that the ongoing Phase 3 PROACT 1 study may be used to support both accelerated and confirmatory approval of rilparencelMore than half of the patients required for the accelerated approval analysis using eGFR slope have been enrolled in the Phase 3 PRO...

August 12, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney Announces Alignment with the FDA on the Accelerated Approval...

ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for full approvalNearly half of the patients required for the accelerated approval analysis using eGFR slope have been enrolledTopline data to support an application for accelerated approval is anticipated in Q2 2027 WINSTON-SALEM, N.C., July 15, ...

July 15, 2025 1 EN
 PRESS RELEASE
Free
PROK PROKIDNEY CORP

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virt...

ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference: H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate:Monday, July 14, 2025Time:1:30pm ETFormat:Fireside ChatWebcast: The live webc...

July 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch